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ABSTRACT Certain short polycations, such as TAT and oligoarginine, rapidly pass through the plasma
membranes of mammalian cells by a mechanism called transduction, as well as by endocytosis and
macropinocytosis. These cell-penetrating peptides (CPPs) can carry with them cargos of 30 amino acids,
more than the nominal limit of 500 Da and enough to be therapeutic. An analysis of the electrostatics of
a charge outside the cell membrane and some recent experiments suggest that transduction may proceed
by molecular electroporation. Ways to target diseased cells, rather than all cells, are discussed.
I. THE PROBLEM OF DRUG DELIVERY
We could cure cancer if we knew how to deliver a drug
intact to the cytosol of every cancer cell, sparing healthy
cells. The circulatory system can deliver a drug to every
cell in the body, and certain chemical tricks protect drugs
from peptidases [1] and nucleases [2]. But it’s harder to
cope with antibodies, spare healthy tissues, and get drugs
past the plasma membrane, which blocks or endocytoses
molecules in excess of 500 Da [3].
This paper is about cell-penetrating peptides and other
cations that can overcome the 500-Da restriction barrier
and about tricks that may spare healthy cells. Section II
describes several cell-penetrating peptides (CPPs), and
section III sketches a variety of therapeutic applications
of CPPs. Section IV reviews basic facts about the lipid
bilayer of the eukaryotic cell. New work on the electro-
statics of the bilayer is presented in section V. Section VI
sketches a model [4, 5] of the transduction of polyargi-
nine and mentions some experimental support [6] which
the model has recently received. Section VII discusses a
broader class of cell-penetrating molecules and suggests
ways to target cancer cells.
II. CELL-PENETRATING PEPTIDES
In 1988, two groups [7, 8] working on HIV reported
that the trans-activating transcriptional activator (TAT)
of HIV-1 can cross cell membranes. The engine driving
this 86-aa cell-penetrating peptide (CPP) is residues 48–
57 grkkrrqrrr which carry a charge of +8e. Other
CPPs were soon found. Antp (aka Penetratin, PEN)
is residues 43–58 rqikiwfqnrrmkwkk of Antennape-
dia, a homeodomain of the fly; it carries a charge of
+7e. The polyarginine Rn carries charge +ne, where
often n = 7, 8, or 9. Other CPPs have been discov-
ered (VP22) or synthesized (transportan). The struc-
tural protein VP22 of the tegument of herpes simplex
virus type 1 (HSV-1) has charge +15e. Transportan
gwtlnsagyllg-k-inlkalaalakkil-amide is a chimeric
peptide constructed from the 12 N-terminal residues of
galanin in the N-terminus with the 14-residue sequence
of mastoparan and a connecting lysine [9]. With its ter-
minal amide group, its charge is +5e.
These and other short, positively charged peptides can
penetrate the plasma membranes of live cells and can tow
along with them cargoes that greatly exceed the 500 Da
restriction barrier. They are promising therapeutic tools
when towing cleverly chosen peptide cargoes of from 8 to
33 amino acids [10–22].
Many early experiments on CPPs were wrong be-
cause the cells were fixed or insufficiently washed. Even
careful experiments sometimes have yielded inconsistent
results—in part because fluorescence varies with the
(sub)cellular conditions and the fluorophores [23].
Yet some clarity is emerging: TAT carries cargoes
across cell membranes with high efficiency by at least two
functionally distinct mechanisms according to whether
the cargo is big or small [24]. Big cargoes, such as pro-
teins or quantum dots, enter via caveolae endocytosis and
macropinocytosis [25, 26], and relatively few escape the
cytoplasmic vesicles in which they then are trapped [24].
Small cargoes, such as peptides of fewer than 30–
40 amino acids, enter both slowly by endocytosis and
rapidly by transduction with direct access to the cytosol,
an unknown mechanism that uses the membrane poten-
tial [24, 27–30]. Peptides fused to TAT enter cells within
seconds [31].
It remains unclear how big cargoes aided by several
CPPs enter cells [32]. For instance, superparamagnetic
nanoparticles encased in aminated dextran and attached
to 45 tat peptides are thought to enter cells by adsorptive
endocytosis[33–35] but they do enter slowly at 4◦ C [36].
III. THERAPEUTIC APPLICATIONS
The use of a cell-penetrating peptide (CPP) to carry
into cells a biologically active peptide of up to some 35
amino acids (aa) allows for 2035 = 3 × 1045 different
peptides and may lead to strikingly smart drugs, some
of which may selectively target tumor cells [10]. I will
now briefly describe 11 promising advances toward this
goal of cell-penetrating-peptide drugs (CPPDs).
The CXC chemokine receptor 4 (CXCR4) is over-
expressed in > 20 types of cancer, including prostate,
breast, colon, and small-cell lung cancer. Snyder et
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al. [11] attached the CXCR4 ligand DV3 to the CPP
TAT and then either to a Cdk2-antagonist peptide (DV3-
TAT-RxL) or to a p53-activating peptide (DV3-{TAT-
p53C’}ri) in which ri means retroinverso [1]. The
DV3+RxL and DV3+p53C’ cargoes respectively con-
sisted of 19 and 33 aa. Both ligand-guided CPPs were
more than twice as effective as unguided CPPs in killing
CXCR4 expressing Namalwa lymphoma cells.
The transcription factor hypoxia-inducible factor-1
(HIF), a master regulator of the hypoxic response, is
itself regulated thru the oxygen-dependent degradation
domains (ODD) of its α-chains (HIFα). The NODD
and CODD peptides respectively are the amino- and
carboxyl-terminal sequences of ODD. Pugh et al. in-
jected TAT fused to CODD (tat-CODD) into sponges
implanted subcutaneously (s.c.) in mice. After 7 days,
they found that tat-CODD but not the control mutant
tat-CODDmut produced blood vessels of increasing den-
sity and complexity [12]. Their results for tat-NODD
were similar. Thus TAT delivery of NODD and CODD
peptides can stimulate angiogenesis and may lead to ther-
apies for ischemic diseases. The cargoes NODD and
CODD respectively were 28 and 19 aa long.
If the DNA-binding ability of the transcription factor
E2F1 is not curtailed as cells traverse and prepare to
exit S phase, then apoptosis is likely. In normal cells,
the retinoblastoma tumor-suppressor protein pRB con-
verts E2Fs from activators to repressors of transcription.
But pRB often is not present in transformed cells. Cy-
clin A/cdk2 also neutralizes E2F1’s DNA-binding abil-
ity. So if one blocked the interaction of cyclin A/cdk2
and E2F1 in cells, then the transcription factor E2F1
would continue to activate transcription after exit from
S phase in cancer cells but not in normal cells equipped,
as they are, with pRB. Apoptosis then would occur in
the transformed cells but not in the normal ones. Chen
et al. [13] used TAT and PEN to carry the synthetic pep-
tides pvkrrlfg and pvkrrldl, which block the inter-
action of cyclin A/cdk2 and E2F1, into U2OS osteosar-
coma cells, T-antigen-transformed WI38/VA13 cells, and
healthy WI38 cells. They found that apoptosis occurred
in and only in the cancer cells [13]. Both cargoes were 8
aa long.
The CPPD PEN-pvkrrldl injected in and near tu-
mors in nude mice that had been s.c. injected with SVT2
cells with altered cyclin D/Rb pathways produced large
areas of apoptosis and necrosis, particularly at the tumor
periphery [14]. PEN-pvkrrlfg had similar effects on
herceptin-resistant mammary tumors from HER2 trans-
genic mice implanted in syngeneic FVB mice [14]. Both
cargoes were 8 aa long.
HDM2 binds and inhibits p53, keeping it at low lev-
els in normal cells. Oncogenic mutations disrupt this
HDM2-p53 equilibrium, allowing p53 to accumulate and
induce stasis or apoptosis. In most cancer cells, p53 is
mutated or HDM2 is overexpressed. Uveal melanomas
(common eye cancers in adults) overexpress HDM2. A
peptide that blocks HDM2 may liberate p53, which may
induce apoptosis in cancer cells but remain inactive in
normal ones. The sequence qetfsdlwkllp (αHDM2) of
the p53 binding site for HDM2 blocks HDM2. TAT-G-
αHDM2 at concentrations of 200–300 µM induces apop-
tosis in MM-23, MM-24, & MM-26 uveal, Y79 & WERI
retinoblastoma, U2OS osteosarcoma, and C33A cervical
cancer cells with little effect on normal cells [15]. Injec-
tion of 107 WERI human retinoblastoma cells produced
intraocular tumors in the anterior chambers of rabbit
eyes. But the injection of TAT-αHDM2 (intraocular con-
centration 200 µM) began to dissolve the tumors into a
fine cloud within 24 hours. A second injection reduced
the viable tumor mass by 76% within 72 hours with no
histologic damage to other ocular tissues. The cargo was
13 aa long.
The CPP rrqrrtsklmkr (“PTD-5,” charge +7e)
joined to the antimicrobial peptide klaklakklaklak
(“KLA”) with a diglycine spacer forms the pro-apoptotic
peptide PTD-5-GG-KLA (“DP1”). Robbins et al. in-
jected 50 µL of 1 mm DP1 or KLA for 11 days into
C57BL/6 mice with single-flank, day-12 MCA205 fi-
brosarcomas. After only 8 days of treatment, DP1 but
not KLA had shrunk the tumors. DP1 but not KLA or
PTD-5 activated caspase-3 and mediated apoptosis [16].
The cargo was 16 aa.
Renal-cell cancer (RCC) is the seventh most common
and is resistant to non-surgical therapies. Sporadic clear-
cell renal cancer often exhibits functional inactivation
of the protein pVHL of the von-Hippel-Lindau (VHL)
gene. Residues 104–123 of a β-sheet of pVHL inhibits
the IGF-I signaling upon which RCC is dependent [17].
Daily intraperitioneal injections of 2 nmol of TAT-FLAG-
pVHL(104–123) arrested and then reduced tumors of
786-O RCC cells in nude mice, while TAT-FLAG had
no effect. (FLAG is the antigen ykddddk.) The cargo
was 27 aa long.
The tumor-suppressor gene 16INK4A often is
inactivated by intragenic mutation, homozygous
deletion, or methylation silencing in many human
cancers, especially pancreatic cancer. Its protein
p16 inhibits the phosphorylation of Rb by cdk-4
and by cdk-6, and so p16 blocks the G1→S phase
transition. Residues 84–103 of p16 are sufficient to
block this transition. The Trojan p16 peptide was
p16(84–103)C linked by a disulfide bond to C-Antp:
daaregfldtlvvlhragarc-crqikiwfqnrrmkwkk.
Trojan p16 (i.p. 100 µg/mouse/day) reduced AsPC-1
and BxPC-3 s.c. tumors respectively by factors of 2 and
5 without hematological cytotoxicity or body weight
loss [18]. The cargo was 22 aa long.
The DOC-2/DAB2 (differentially expressed in ovarian
cancer-2/disabled 2) protein often is lost in prostate can-
cer. As part of the homeostatic machinery in the nor-
mal prostate epithelium, DOC-2/DAB2 modulates the
Grb2-SOS-MAPK signal axis. The small peptide fql-
rqpplvpsrkge is less immunogenic than the protein
DOC-2/DAB2 but still has some of its ability to inter-
act with SH3 domains. Hsieh et al. used the CPP R11
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to carry this peptide into cells. The CPPD r11-ggg-
fqlrqpplvpsrkge at 5 µM for 3 hours inhibited the
growth of LNCaP and C4-2 prostate-cancer cells. [19]
The cargo was 18 aa long.
The peptide p53C′, derived from the K-rich C-
terminal domain of p53, activates specific DNA bind-
ing by p53, activates wild-type p53, restores function
to several p53 contact mutants, and induces apopto-
sis or G1 growth arrest in cancer cells but not in nor-
mal ones [20]. The retro-inverso [1] D-isomer TAT-
p53C′ri rrrqrrkkrgygkkhrstsqgkksklhssharsg resists prote-
olysis better than the L-isomer p53C′-TAT. TAT-p53C′ri
induces G1 cell-cycle arrest and senescence better than
p53C′-TAT in murine TA3/St mammary cancer cells,
which express wild-type p53, and induces the transcrip-
tion of p53 from a wild-type p53 expression vector in
p53-null, H1299 lung-cancer cells [20]. Injections (i.p.) of
600 µg of TAT-p53C′ri once a day for 12 days inhibited
solid-tumor growth in mice and led to a 6-fold increase in
longevity in mice with terminal peritoneal carcinomato-
sis. Sixteen injections (i.p.) of 900 µg of TAT-p53C′ri
over 20 days cured 50% of mice with terminal peritoneal
lymphoma [20]. The cargo was 23 aa long.
Residues 1–15 of the human ventricular myosin light
chain-1 (VLC-1) binds to actin, targets the actin/MLC-
1 interaction, and improves the contraction of isolated
perfused hearts [21]. VLC-1 fused to TAT entered
adult cardiomyocytes with high efficiency, accumulated
in the actin-containing I-band of their sarcomeres, and
enhanced their contractility without changing their my-
oplasmic Ca2+ levels [22]. The cargo was 15 aa long.
In these transduction experiments, the heaviest cargo
was 33 amino acids. In my somewhat casual litera-
ture search, I found no biomedical articles describing the
transduction of heavier cargoes. In the biophysical ex-
periments, the cargoes respectively were 20, 22, and 26
aa (apart from a tiny rhodamine tag) [24], and just a
∼400 Da fluorophore [37].
IV. MAMMALIAN PLASMA MEMBRANES
The plasma membrane of a mammalian cell is a lipid
bilayer that is 4 or 5 nm thick. Of the four main phos-
pholipids in it, three—phosphatidylethanolamine (PE),
phosphatidylcholine (PC), and sphingomyelin (SM)—are
neutral, and one, phosphatidylserine (PS), is negatively
charged. In live cells, PE and PS are mostly in the cy-
tosolic layer, and PC and SM in the outer layer [38, 39].
Aminophospholipid translocase (flippase) moves PE and
PS to the inner layer; floppase slowly moves all phospho-
lipids to the outer layer [38].
Glycolipids make up about 5% of the lipid molecules
of the outer layer of a mammalian plasma membrane
where they may form lipid rafts. Their hydrocarbon
tails normally are saturated. Instead of a modified phos-
phate group, they are decorated with galactose, glucose,
GalNAc = N-acetylgalactosamine, and other sugars. The
most complex glycolipids—the gangliosides—have nega-
tively charged sialic-acid (NANA) groups.
A living cell maintains an electrostatic potential of be-
tween 20 and 120 mV across its plasma membrane. The
electric field E within the membrane points into the cell
and is huge, about 15 mV/nm or 1.5 × 107 V/m if the
potential difference is 60 mV across a membrane of 4
nm. Conventionally, one reports membrane potentials
as the electric potential inside the cell minus that out-
side, so that here ∆V = −60 mV. Near but outside
the membrane, this electric field falls-off exponentially
E(r) = E exp(−r/D`) with the ratio of the distance r
from the membrane to the Debye length D`, which is of
the order of a nanometer. The rapid entry of TAT fused
to peptides is frustrated only by agents that destroy the
electric field E [24].
Most of the phospholipids of the outer leaflet of the
plasma membrane are neutral PCs & SMs. They vastly
outnumber the negatively charged gangliosides, which are
a subset of the glycolipids, which themselves amount only
to 5% of the outer layer. Imagine now that polyarginine-
cargo molecules are in the extra-cellular environment.
Many of them will be pinned down by the electric
field E(r) just outside the membrane, their positively
charged guanidinium groups interacting with the neg-
ative phosphate groups of neutral dipolar PC & SM
head groups [29]. (Other CPP-cargo molecules will stick
to negatively charged gangliosides and to glycosamino-
glycans (GAGs) attached to transmembrane proteogly-
cans (PGs); these slowly will be endocytosed. PGs with
heparan-sulfate GAGs are needed for TAT-protein endo-
cytosis [40].) It is crucial that the dipolar PC & SM head
groups are neutral and so do not cancel or reduce the pos-
itive electric charge of a CPP-cargo molecule. The net
positive charge of a CPP-cargo molecule and the nega-
tively charged PSs under it on the inner leaflet form a
kind of capacitor.
V. MEMBRANE ELECTROSTATICS
A recent calculation [4] of the electrostatic potential
due to a charge outside the phospholipid bilayer of a eu-
karyotic cell shows how effectively this plasma membrane
insulates the cell from external charges.
The electrostatic potential in the lipid bilayer V`(ρ, z)
due to a charge q at the point (0, 0, h) on the z-axis, a
height h above the interface between the lipid bilayer and
the extra-cellular environment, is
V`(ρ, z) =
q
4pi0w`
∞∑
n=0
(pp′)n
(
1√
ρ2 + (2nt+ h− z)2
− p
′√
ρ2 + (2(n+ 1)t+ h+ z)2
)
(1)
in which t is the thickness of the lipid bilayer, w` =
(w + `)/2 is average of the relative permittivities of the
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extra-cellular fluid w and the lipid bilayer `, and p and
p′ are the ratios
p =
w − `
w + `
and p′ =
c − `
c + `
(2)
which lie between 0 and 1, c being the relative permittiv-
ity of the cytosol [4]. The potential in the extra-cellular
medium is
Vw(ρ, z) =
q
4pi0w
(
1
r
+
p√
ρ2 + (z + h)2
− w`
2w`
∞∑
n=1
pn−1p′n√
ρ2 + (z + 2nt+ h)2
)
(3)
in which r =
√
ρ2 + (z − h)2 is the distance from the
charge q [4]. The potential in the cytosol due to the
same charge q is
Vc(ρ, z) =
q `
4pi0w``c
∞∑
n=0
(pp′)n√
ρ2 + (2nt+ h− z)2 . (4)
where `c is the mean relative permittivity `c = (` +
c)/2 [4].
If one seeks the potential only directly above or be-
low the charge, that is, for ρ = 0, then these formulas
become simpler and may be expressed in terms of the
Lerch transcendent
Φ(z, s, α) =
∞∑
n=0
zn
(n+ α)s
. (5)
For ρ = 0, the potential is
V`(0, z) =
q
4pi0w`
∞∑
n=0
(pp′)n
(
1
2nt+ h− z
− p
′
2(n+ 1)t+ h+ z
)
=
q
8pi0w`t
[
Φ
(
pp′, 1,
h− z
2t
)
− p′Φ
(
pp′, 1, 1 +
h+ z
2t
)]
(6)
in the lipid bilayer,
Vw(0, z) =
q
4pi0w
[
1
|z − h| +
p
z + h
(7)
− w`
2w`p
(
1
2t
Φ(pp′, 1,
z + h
2t
)− 1
z + h
)]
in the extracellular environment, and
Vc(0, z) =
q `
8pi0w``ct
Φ(pp′, 1,
h− z
2t
). (8)
in the cytosol.
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FIG. 1: The potentials (6–8) above, Vw(0, z) (blue), and be-
low, V`(0, z) (red) and Vc(0, z) (blue), a unit charge q = |e| at
(ρ, z) = (0, 0) are plotted for a lipid bilayer of thickness t = 5
nm. The green dotted curve follows the simple approximation
(10).
In and near the extracellular region, these potentials
are fairly well approximated by the simple formulas
Vw(0, z) ≈ q
4pi0w
(
1
|z − h| +
p
z + h
)
(9)
V`(0, z) ≈ q
4pi0wl |z − h| (10)
which hold when the lipid bilayer is infinitely thick. But
the potential V`(0, z) drops significantly below the sim-
ple formula (10) as z descends deeper into the bilayer
and nearly vanishes at the lipid-cytosol interface as does
Vc(0, z) in the cytosol.
For a unit charge q = |e| at (ρ, z) = (0, 0), the poten-
tials (6–8) are plotted in Fig. 1: Vw(0, z) (blue), V`(0, z)
(red), and Vc(0, z) (blue). The green dotted curve follows
the simple approximation (10) to V`(0, z). The potential
V`(0,−t) at the interface between the cytosol and the bi-
layer is 6.6 × 10−4 V, so that a unit charge there would
have an electrostatic energy (due to the charge |e| at
(0, 0)) of only about kTb/40 at body temperature.
Fig. 2 plots the potentials (6–8) due to a unit charge
at (ρ, z) = (0, 0) for lipid bilayers of thicknesses t = 2,
3, 4, and 5 nm. Even for a bilayer as thin as 2 nm,
the potential Vc(0,−t) directly below the charge at the
interface between the cytosol and the bilayer is less than
a tenth of kTb/|e|.
These potentials and figures illustrate the extraordi-
nary electrostatic insulation provided by the lipid bilayer.
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FIG. 2: The potentials (7, 6, & 8) above Vw(0, z) (blue) and
below V`(0, z) (red) and Vc(0, z) (blue) a unit charge q = |e|
at (ρ, z) = (0, 0) are plotted for lipid bilayers of thickness
t = 2, 3, 4, and 5 nm. Note that the potential at the interface
between the cytosol and the bilayer is less than a tenth of kT
even for a bilayer as thin as 2 nm.
VI. ELECTROPORATION MODEL
A. Electroporation
Somewhat paradoxically, the remarkable electrostatic
insulation provided by the lipid bilayer makes membrane
proteins more sensitive to charges lying outside the cell
and also makes cells more vulnerable to electroporation.
The reason for both of these effects is that the electric
field E in the lipid bilayer due to a charge q at the in-
terface between the bilayer and the extracellular environ-
ment is
E = − [V`(0, 0)− V`(0,−t)] zˆ
t
(11)
apart from the screening effects of counterions. Since
even a charge q = ±10e makes a potential V`(0,−t) at
z = −t that is less than kTb/|e|, this electric field is
approximately
E ≈ −V`(0, 0) zˆ
t
(12)
which is larger than if the potential V`(0,−t) were more
significant.
Electroporation is the formation of pores in membranes
by an electric field. Depending on the duration of the
field and the type of cell, an electric potential difference
TABLE I: The voltage differences ∆VCPP + ∆VNaCl (mV)
across the plasma membrane induced by an RN oligoarginine
as an α-helix, a random coil, or a β-strand and by the ions of
156 mM Na+ and Cl− reacting to it. The resting transmem-
brane potential − 120 < ∆Vcell < −20 mV is not included.
N RN α-helix RN random coil RN β-strand
5 − 144± 4 − 154± 3 − 148± 4
6 − 174± 4 − 173± 4 − 168± 1
7 − 206± 4 − 201± 3 − 189± 2
8 − 232± 3 − 228± 1 − 199± 5
9 − 256± 6 − 246± 2 − 205± 4
10 − 281± 2 − 260± 5 − 210± 4
11 − 306± 5 − 260± 3 − 218± 4
12 − 323± 4 − 261± 4 − 213± 2
across a cell’s plasma membrane in excess of about 200
mV will create pores.
There are two main components to the energy of a
pore. The first is the line energy 2pirγ due to the linear
tension γ, which is of the order of 10−11 J/m. The second
is the electrical energy −0.5∆Cpir2(∆V )2 in which ∆V
is the voltage across the membrane and ∆C = Cw−C` is
the difference between the specific capacity per unit area
Cw = w0/t of the water-filled pore and that C` = `0/t
of the pore-free membrane of thickness t. There also is
a small term due to the surface tension Σ of the plasma
membrane of the cell, but this term usually is negligible
since Σ is of the order of 2.5×10−6 J/m2 [41]. The energy
of the pore in a plasma membrane is then [42–46]
E(r) = 2pirγ − pir2Σ− 12pir2∆C (∆V )2. (13)
This energy has a maximum of
E(rc) =
2piγ2
∆C(∆V )2 + 2Σ
≈ 2piγ
2
∆C(∆V )2
(14)
at the critical radius
rc =
2γ
∆C (∆V )2 + 2Σ
≈ 2γ
∆C (∆V )2
. (15)
The chance of a pore forming rises steeply with the mag-
nitude of the voltage and falls with the radius of the pore.
If the transmembrane potential ∆V is turned off before
the radius of the pore reaches rc, then the radius r of the
pore usually shrinks quickly (well within 1 ms [43]) to a
radius so small as to virtually shut-down the conductivity
of the pore. This rapid closure occurs because in (13) the
energy 2pirγ dominates over −pir2Σ, the surface tension
Σ being negligible. Such a pore is said to be reversible.
But if ∆V remains on when r exceeds the critical radius
rc, then the pore usually will grow and lyse the cell; such
a pore is said to be irreversible.
The formula (15) provides an upper limit on the radius
of a reversible pore. This upper limit drops with the
square of the transmembrane voltage ∆V from rc = 3.6
nm for ∆V = −200 mV, to 1.6 nm for ∆V = −300, and
to 0.9 nm for ∆V = −400 mV.
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The time t` for a pore’s radius to reach the critical
radius rc is the time to lysis; it varies greatly and ap-
parently randomly even within cells of a given kind. In
erythrocytes, its mean value drops by nearly an order of
magnitude with each increase of 100 mV in the trans-
membrane potential [43] and is about a fifth of a second
when ∆V = −300 mV.
The chance of a potential ∆V forming a pore
of radius r is proportional to the Boltzmann factor
exp(−E(r)/(kT )). The higher the potential ∆V and the
narrower the pore, the greater the chance of pore forma-
tion.
B. The Model
In the model advanced in references [4, 5], a pol-
yarginine sticks to the cell membrane as its guani-
dinium groups electrostatically interact with the phos-
phate groups of the outer leaflet of the phospholipid bi-
layer. If the positive charge of the polyarginine exceeds
about 8|e|, then it can raise the transmembrane poten-
tial above the threshold for electroporation, some −200
mV [41–46].
The transmembrane potential ∆V is the sum of three
terms
∆V = ∆Vcell + ∆VCPP + ∆VNaCl (16)
the resting transmembrane potential ∆Vcell of the cell
in the absence of CPPs, the transmembrane potential
∆VCPP due to an oligoarginine or other CPP, and the
transmembrane potential ∆VNaCl due to the counterions
of the extracellular medium. The resting transmembrane
potential ∆Vcell of the cell varies between about 20 mV to
more than 70 mV, depending upon the type of cell. Ide-
ally, it is measured experimentally. The transmembrane
potential ∆VCPP due to an oligoarginine or to some other
positively charged CPP may be determined from the for-
mulas (1–8) for the potential of a charge outside a mem-
brane [4]. The transmembrane potential ∆VNaCl due to
the counterions of the extracellular medium requires a
Monte Carlo simulation of the Na+, Cl−, and other ions
of the extracellular medium in the electrostatic potential
Vcell + VCPP . This simulation was performed in [4] with
the aid of equations (1–8). The lipid bilayer insulates
the extracellular counterions from the potential due to
the counterions of the cytosol, however, so their potential
may be neglected in the simulation of the extracellular
counterions.
The values of ∆VCPP + ∆VNaCl found in Monte Carlo
simulations [4] of the salt around an RN oligoarginine
are listed in the table. A resting transmembrane poten-
tial −120 < ∆Vcell < −20 mV should be added to these
values of ∆VCPP + ∆VNaCl to obtain the full transmem-
brane potential ∆V . For N > 8, the transmembrane
potential ∆V can exceed −200 mV which is enough [41–
46] to cause electroporation in common eukaryotic cells.
In references [5] and [4], it was pointed out that one
way to test the model advanced in those papers would be
to look for the formation of reversible pores by detect-
ing transient (ms) changes in the conductance of mem-
branes exposed to CPPs such as R9. Such experiments
have now been done. Using the planar-phospholipid-
bilayer method, Herce et al. found that R9 induced tran-
sient ionic currents through model phospholipid mem-
branes [6]. They estimated that the mean radius of these
pores to be 0.66 nm, which is safely below the limiting
critical radius (15) of between 0.9 and 3.6 nm for the volt-
age range of −400 ≤ ∆V ≤ −200 mV. Moreover, using
the patch-clamp technique, they found that R9 induced
transient ionic currents through the membranes of both
freshly isolated human umbilical-artery (HUA) smooth-
muscle cells and cultured osteosarcoma cells [6]. These
experimental confirmations of the predictions made in
references [5] and [4] lend some support to the model ad-
vanced in these papers and sketched in this subsection,
but they do not prove that it is correct. It is, in any case,
a continuum model of a molecular effect, and it may be
consistent with the one simulated in reference [6].
VII. SMART DRUGS
Oligoarginines and other cell-penetrating peptides can
carry cargos of up to 4000 Da across the lipid bilayer
of eukaryotic cells by molecular electroporation [4, 5].
This ability to transduce cargos that substantially exceed
the nominal restriction barrier of 500 Da of the “rule of
five” [3] makes possible therapies like those sketched in
section III.
But we also need a way of targeting cancer cells. One
way to do this has been suggested by Tsien [10]. His idea
is to attach a negatively charged molecule, an anion, to
the CPP-cargo molecule by a polypeptide linker that is
cut primarily by peptidases that are over-expressed by
the targeted cells. The geometry he proposed is
anion−linker−CPP−cargo (17)
in which the hyphens represent covalent bonds. The
cargo is the therapeutic compound. It might be one of
the peptides of ([10]–[22]), which consisted of between
8 and 33 amino acids, or simply a cytotoxin. If the
negative charge of the anion lowers total charge of the
anion-linker-CPP-cargo molecule below a few |e|, then
it will not enter the cell by transduction because, in the
model [4, 5], its transmembrane potential ∆V will be too
small to cause electroporation. (The anion-linker-CPP-
cargo molecule might enter the cell by endocytosis, but
then it would risk destruction as the pH of the endosome
dropped to that of a lysosome.) Metastatic cancer cells
over-express certain transmembrane peptidases. So to
target them, one would pick a linker that is cut by one
of these over-expressed transmembrane peptidases.
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A. Better Geometries
One may improve the selectivity of such a smart drug
by attaching two or more anions to the positively charged
CPP-cargo by two or more different linkers that are cut
primarily by different peptidases that are over-expressed
by the targeted cells. A simple geometry for two anions
and two different linkers is
anion1−linker1−CPP−cargo−linker2−anion2. (18)
To attach more than two anions by more than two dif-
ferent linkers, one can prepare an oxidizing solution of
two classes of molecules. A simple example of a molecule
of the first class is the molecule (18) with an extra cys-
teine (C)
anion1−linker1−C−CPP−cargo−linker2−anion2 (19)
where the hyphens represent covalent bonds. Other ex-
amples of first-class molecules contain more cysteines to
the left and/or right of the CPP-cargo moiety.
In a more compact notation in which A stands for an
anion and L for a linker, two more examples of first-class
molecules are
A1−L1−C−C−CPP−cargo−C−C−L2−A2 (20)
with four extra cysteines and
A1−L1−C−C−C−CPP−cargo−C−C−C−L2−A2
(21)
with six. First-class molecules must have their cysteines
closer than any of the linkers to the CPP-cargo moiety;
otherwise the cutting of a single linker could set adrift
more than one anion.
Molecules of the second class consist of a cysteine cova-
lently fused to a linker that in turn is covalently fused to
an anion; that is, second-class molecules are of the form
C−Lk−Ak (22)
in which Lk is a linker cleavable by a peptidase over-
expressed by the target cells and Ak is an anion.
In an oxidizing solution of these two classes of
molecules, a cysteine of a second-class molecule can form
a disulfide bond with a cysteine in a first-class molecule.
Thus, smart drugs can form in which three or more an-
ions are fused to the CPP-cargo molecule by linkers that
can be cut by peptidases over-expressed by the target
cells. For instance, an oxidizing solution of the first-class
molecule (19) and the second-class molecule (22) would
make the smart drug shown in Fig. 3. Similarly, an ox-
idizing solution of the first-class molecule (20) and the
second-class molecule (22) for k = 3, 4, 5, and 6 would
form the smart drug of Fig. 4.
Of course, undesirable disulfide bonds also would form.
One way to suppress unwanted disulfide bonds is to
titrate a dilute reducing solution of different second-class
molecules (22) into an oxidizing solution of first-class
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 – C – CPP – cargo – L
2
 - A
2
I
 I
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3
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L
3
FIG. 3: A smart drug consisting of a CPP-cargo molecule
and three anions fused to it by three different linkers that
are cut primarily by peptidases over-expressed mainly by the
targeted cells. Here A, C, and L respectively stand for anion,
cysteine, and (8 aa) linker. The hyphens and vertical lines
represent covalent bonds.
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A1-L1-C-C-CPP-cargo-C–C-L2-A2
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FIG. 4: A smart drug consisting of a CPP-cargo molecule
and six anions fused to it by six different linkers that are cut
primarily by peptidases over-expressed mainly by the targeted
cells. A, C, L, hyphens, and vertical lines are as in Fig. 3.
molecules such as (19, 20, or 21). The order of the
linkers and anions does not matter as long as they are
different and are cut primarily by peptidases that are
over-expressed mainly by the target cells.
To achieve maximum specificity, it is desirable that the
negative charge of each anion reduce the positive charge
of the CPP to 4|e| or less, for in this case, the CPP-
cargo molecule is not transduced until all the linkers are
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cleaved. Thus, if the CPP is the oligoarginine R9 with
charge 9|e|, then a smart drug like that in Fig. 4 would
have six anions of charge −5|e| for a total charge of q =
−21|e|. Such smart drugs would be negatively charged.
By using well-chosen linkers, disulfide bonds, CPP’s,
and cell-penetrating molecules (CPM’s) such as cationic
lipids, one can make a very wide variety of smart drugs.
B. Linkers
Linkers are essential to the selectivity of the smart
drugs sketched in this section. Each linker must be a
short peptide that is cut primarily by a peptidase that is
over-expressed mainly by the targeted cells.
MT1-MMP is a type-1 transmembrane proteinase es-
sential for skeletal development, metastasis, and angio-
genesis. The Burnham Institute’s cut database [47]
lists 37 eight-aa-long sequences that have been shown
by experiment to be cut by MT1-MMP and that
are not known to be cut by other human pepti-
dases: psqg-qkve, npmg-sepv, gyfg-dpla, nlag-
ilke, glrg-lqgp, lrrl-lglf, aveg-sgks, dlsl-
ispl, lisp-laqa, geyr-tnpe, psqg-qkve, tkrd-lals,
rvlg-lete, rllg-lfge, dpfr-lqct, lppg-lplt, ppsy-
lgdr, qlyg-gesg, nffp-rkpk, dpsa-imap, qglk-
wqhn, fciq-nytp, aepw-tvrn, qqly-gges, pqpr-
ttsr, aqlg-vmqg, mdet-mkel, kayk-sele, llil-
sdvn, lils-dvnd, dshs-lttn, lrgd-fssa, nmid-aatl,
kaiq-ltyn, glrg-lqgp, sser-ssts, and tsgg-yify.
MT1-MMP cuts these 37 octapeptides at the hyphens.
Although 37 sequences may seem so numerous as to
be unselective, in fact, they are 37 out of 208 =
25, 600, 000, 000 possible 8-aa sequences.
The ADAMs are membrane proteins that have both
a disintegrin domain and a metalloprotease domain.
ADAM9, 10, 12, 15, and 17 have been found in cancer
cells. ADAM17 (aka tace) sheds and/or processes tnfα,
tgfα, app, amphiregulin, p75tnfr, p55tnfr, trance,
L-selectin, IL-6 receptor, IL-1 receptor II, Notch1 re-
ceptor, growth hormone-binding protein, muc1, and
transmembrane collagen XVII [48]. The Burnham cut
database [47] lists nine eight-amino-acid-long sequences
that have been shown by experiment to be cut by
adam17 and that are not known to be cut by any
other human peptidase: dlla-vvaa, nsar-segp, kldk-
sfsm, lpvq-dsss, wtgh-stlp, rlrr-glaa, ksmk-
thsm, rveq-vvkp, and vaaa-vvsh. The cuts occur at
the hyphens.
Prostate-specific membrane antigen (PSMA) is a glu-
tamate carboxypeptidase II highly expressed by prostate
epithelial cells and by the neovasculature of many tumor
types but not by endothelial cells in normal tissue [49].
Denmeade et al. have found [49] that the substrate
APA−D−E∗E∗D−E (23)
is stable in blood but is cut—at the second hyphen—
by PSMA. Here APA is 4-n[n-2,4diamino-6-pteridinyl-
A3
I
L3
I
C
I
A1-L1-S-C-CPP-cargo-C–T-L2-A2
I
C
I
L4
I
A4
I
Pi
I
FA
I
Pi
I
Gl
I
(FA)2
FIG. 5: A smart drug consisting of a CPP-cargo molecule and
four anions fused to it by four different linkers that are cut
primarily by peptidases over-expressed mainly by the targeted
cells. Pi stands for inorganic phosphate, FA for fatty acid, and
Gl for glycerol. A, C, L, hyphens, and vertical lines are as in
Fig. 3.
methyl)-n-methylamino-benzoate], and the asterisks rep-
resent γ-linkages, while the hyphens stand for the usual
α-linkages.
C. Cell-Penetrating Molecules
Two features of oligoarginines allow them to penetrate
through cell membranes: a positive charge exceeding 8|e|
and several guanidinium groups. Thus any molecule with
several guanidinium groups and a positive charge ex-
ceeding 8|e| may be as good a cell-penetrating molecule
(CPM) as the oligoarginines considered in this paper.
Cationic lipids can penetrate cell membranes; they
form another category of cell-penetrating molecules. One
design for a cationic lipid has one or several serines S
and/or threonines T to the left and/or right of the CPP-
cargo moiety. Thus an example of a first-class molecule
for a cationic-lipid CPM is
A1−L1−S−C−CPP−cargo−C−T−L2−A2. (24)
To complete this first-class molecule one would use the
same kind (22) of second-class molecule and third-class
molecules that are either a fatty acid FA fused to an in-
organic phosphate group Pi by an acyl-phosphate bond
FA−Pi (25)
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or a phospholipid without its polar head group
(FA)2=Gl−Pi (26)
in which Gl is a glycerol. One would make the cationic-
lipid CPM by fusing the second-class molecules to
the cysteines C by disulfide bonds and the third-class
molecules to the hydroxyl groups of serines S and thre-
onines T by ester bonds. The resulting smart drug is il-
lustrated in Fig. 5. Such cationic-lipid smart drugs with
various numbers of anions, linkers, and lipids may be able
to carry therapeutic cargos across the cell membrane.
D. Stability
Blood has peptidases that cut peptides and RNAses
that cut RNAs, but there are some biochemical tricks
that can increase the stability of peptides and RNAs in
smart drugs. One may use right-handed amino acids to
frustrate peptidases. A peptide made of right-handed
amino acids in reverse order can have similar biochemical
properties to its normally ordered left-handed twin [1].
Such retro-inverso peptides are more stable in the body
and were used in several of the therapeutic experiments
sketched in section III. RNAs made with 2’-O-methyl-
modified nucleotides with phosphorothioate linkages re-
sist RNAses [50]. The wide class of cell-penetrating
molecules may have members that are stable in the hu-
man body and unlikely to stimulate an immune response.
E. Ligands and Antibodies
What is really needed for specificity is knowledge of
what distinguishes the surface of a cancer cell from that
of a healthy cell. Cancer cells over-express many recep-
tors, such as the CXC chemokine receptor 4 (CXCR4),
the specific neurokinin-1 (NK-1) receptor, folate recep-
tors (FRs), the G-protein-coupled protease-activated re-
ceptor PAR-1, and receptors for many regulatory pep-
tides. Metastatic cancer cells over-express many trans-
membrane peptidases. A reasonably complete charac-
terization of the distinguishing features of the surfaces
of cancer cells would advance the development of com-
pounds that bind to these features. Such an artificial
feature-ligand (FL) could guide a CPP-cargo molecule
to cancer cells. The simplest geometry would be
FL−L1−CPP−cargo−L2−A (27)
in which the linkers L1 and L2 are cleavable by peptidases
overexpressed by the cancer cell that overexpresses the
feature F .
VIII. SUMMARY
In a model, which recently has received some exper-
imental support, polyarginines carry cargos by molecu-
lar electroporation across the cell membrane. They and
other cell-penetrating peptides (CPPs) as well as cell-
penetrating molecules (CPMs), such as cationic lipids,
can transduce therapeutic cargos that greatly exceed the
500 Da restriction barrier. They may solve part of the
drug-delivery problem.
The use of well chosen linkers and anions can help tar-
get cancer cells and spare healthy ones. The development
of really smart drugs, however, requires a more complete
characterization of the differences between the surfaces
of cancer cells and those of normal cells.
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